Sfoglia per AUTORE
ROSSI D
Collezione AO Cuneo

  

Items : 12

Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study. in American journal of hematology / Am J Hematol. 2023 Feb;98(2):E24-E27. doi: 10.1002/ajh.26779. Epub 2022 Nov 25.

2023
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Levi S; Trentin L; Foà R; Cuneo A; Herishanu Y; Gentile M; Perry C; Gattei V; Gaidano G; Rossi D; Neri A; Olivieri J; Bomben R; Zucchetto A; Visentin A; Loseto G; Pietrasanta D; Chiarenza A; Braester A; Murru R; Aviv A; Varettoni M; Coscia M; Tadmor T; Shvidel L; Sportoletti P; Laurenti L; Reda G; Ruchlemer R; et alii...

Genetic and phenotypic attributes of splenic marginal zone lymphoma. in Blood / Blood. 2022 Feb 3;139(5):732-747. doi: 10.1182/blood.2021012386.

2022
AO Cuneo
AOU Novara
AOU Alessandria

Rossi D; Ponzoni M; Mazzucchelli L; Zucca E; Cavalli F; Paulli M; Piris MA; Traverse-Glehen A; Tzankov A; Campo E; Pileri SA; Dirnhofer S; De Leval L; Bhagat G; Bertoni F; Zinzani PL; Khiabanian H; Zaja F; Calcinotto A; Zenz T; Vitolo U; Visco C; Walewska R; Vanini G; Tousseyn T; Tucci A; Tarella C; Thieblemont C; Tapia G; et alii...

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. in American journal of hematology / Am J Hematol. 2021 May 1;96(5):E168-E171. doi: 10.1002/ajh.26127. Epub 2021 Feb 24.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Gentile M; Gattei V; Foà R; Ferrarini M; Polliack A; Gaidano G; Trentin L; Cuneo A; Fronza G; Cutrona G; Rossi D; Di Raimondo F; Neri A; Bomben R; Biagi A; Del Giudice I; Angeletti I; Galimberti S; Rago A; Caracciolo D; Cassin R; D'Arrigo G; Mendicino F; Botta C; Martino EA; Vigna E; Zucchetto A; Rossi FM; Scortechini I; et alii...

Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. in Leukemia / Leukemia. 2021 Jan;35(1):235-238. doi: 10.1038/s41375-020-0833-x. Epub 2020 Apr 14.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Sportoletti P; Laurenti L; Gattei V; Gaidano G; Polliack A; Foà R; Rossi D; Cuneo A; Di Raimondo F; Rigolin GM; Bomben R; Biagi A; Del Giudice I; Angeletti I; Rago A; Arrigo G; Vigna E; Botta C; Tripepi G; Fraticelli V; Zucchetto A; Scortechini I; Loseto G; Consoli U; Rossi FM; Pietrasanta D; Murru R; Chiarenza A; Condoluci A; et alii...

TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. in American journal of hematology / Am J Hematol. 2021 Aug 1;96(8):E306-E310. doi: 10.1002/ajh.26235. Epub 2021 May 25.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Gentile M; Gattei V; Ferrarini M; Foà R; Polliack A; Trentin L; Cuneo A; Gaidano G; Di Raimondo F; Rossi D; Olivieri J; Jaksic O; Bomben R; Neri A; Fronza G; Rago A; Angeletti I; Cutrona G; Del Giudice I; Biagi A; Galimberti S; D'Arrigo G; Al-Janazreh H; Martino EA; Vigna E; Tripepi G; Zucchetto A; Rossi FM; Recchia AG; et alii...

Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials. in American journal of hematology / Am J Hematol. 2021 Aug 1;96(8):E269-E272. doi: 10.1002/ajh.26201. Epub 2021 May 3.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

D Arrigo G; Murru R; Gentile M; Gattei V; Polliack A; Trentin L; Gaidano G; Di Raimondo F; Cuneo A; Cutrona G; Rossi D; Menichini P; Olivieri J; Fronza G; Monti P; Del Giudice I; Bomben R; Neri A; Angeletti I; Biagi A; Rago A; Martino EA; Cassin R; Galimberti S; Foà R; Ferrarini M; Scortechini I; Rossi FM; Zucchetto A; et alii...

Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. in European journal of haematology / Eur J Haematol. 2021 Apr;106(4):493-499. doi: 10.1111/ejh.13573. Epub 2021 Jan 28.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Gentile M; Gattei V; Ferrarini M; Foà R; Trentin L; Polliack A; Gaidano G; Cuneo A; Di Raimondo F; Rossi D; Jaksic O; Monti P; Cutrona G; Bomben R; Neri A; Fronza G; Menichini P; Biagi A; Del Giudice I; Angeletti I; Rago A; Galimberti S; Cassin R; D'Arrigo G; Mendicino F; Martino EA; Vigna E; Al-Janazreh H; Zucchetto A; et alii...

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. in Leukemia / Leukemia. 2020 Sep;34(9):2354-2363. doi: 10.1038/s41375-020-0959-x. Epub 2020 Jul 9.

2020
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Foà R; Rambaldi A; Montserrat E; Rossi G; Stamatopoulos K; Coscia M; Stavroyianni N; Strugov V; Tam C; Zdrenghea M; Shah N; Shrestha A; Stanca O; Ortiz Pareja M; Papaioannou M; Rossi D; Kalashnikova O; Hakobyan Y; Doubek M; Enrico A; Dimou M; Andres M; Chiarenza A; Nikitin E; Dos Santos G; Barna G; Yassin M; Pocali B; Sportoletti P; et alii...

HIF-1? is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. in Haematologica / Haematologica. 2020 Apr;105(4):1042-1054. doi: 10.3324/haematol.2019.217430. Epub 2019 Jul 9.

2020
ASL Asti
AO Cuneo
AOU Città della Salute di Torino
ASL Vercelli
AOU Novara

Boccadoro M; Gattei V; Foà R; Massaia M; Gaidano G; Zenz T; Bernardi R; Mauro FR; Laurenti L; Del Poeta G; Kodipad AA; Omedè P; Magliulo D; Rossi D; Marchetti M; Bonello L; Pozzato G; Bo MD; Kopecka J; Bomben R; Salvetti C; Riganti C; Todaro M; Vitale C; Griggio V; Coscia M;

Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. in Leukemia / Leukemia. 2015 Jun;29(6):1360-5. doi: 10.1038/leu.2015.21. Epub 2015 Feb 4.

2015
AO Cuneo

Riminucci M; Nicolai E; Trastulli F; Campanelli M; Autore F; Laurenti L; Rossi D; Sacchetti GM; Bellò M; Coscia M; Morabito F; Gentile M; Rago A; Cimino G; Biggi A; Paoloni F; Chauvie S; Mauro FR; Gaidano G; Guarini A; Gallamini A; Foà R;

Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. in Haematologica / Haematologica. 2014 Sep;99(9):e159-61. doi: 10.3324/haematol.2014.106740. Epub 2014 Jun 27.

2014
AO Cuneo

Massaia M; Morra E; Nichelatti M; De Paoli L; Rossi D; Frustaci AM; Gallamini A; Motta M; Ghia P; Cascavilla N; Orlandi E; Petrizzi VB; Coscia M; Gaidano G; Tedeschi A; Montillo M;

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21.

2014
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AO Cuneo
AOU Città della Salute di Torino

Montefusco V; Zambello R; Gottardi D; Franceschini L; Grasso M; Vincelli ID; Benevolo G; Levi A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Palumbo A; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; et alii...